Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With Sulfasalazine
Recruiting
Observational Study
Inflammatory Arthritis
Diabetes (DM)
Rheumatoid Arthritis (RA)
Type 1 Diabetes Mellitus
Type 2 Diabetes (T2DM)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 75 (estimated)
- Sponsor
- Klavs Würgler Hansen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to examine whether the blood test Hemoglobin A1c (HbA1c) gives an accurate picture of blood glucose levels in patients with inflammatory arthritis who are treated with sulfasalazine. HbA1c is widely used to diagnose and monitor diabetes, but sulfasalazine can shorten red blood cell lifespan and thereby lower HbA1c values independently of actual glucose levels.
This ma…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 years
* Treatment with sulfasalazine for at least 2 months prior to inclusion
* Inflammatory arthritis diagnosis (Reumatoid Arthritis, Reaktive Arthritis, Axial spa, Psoriatic spondylitis, and Juvenil artrit)
* HbA1c ≥38 mmol/mol obtained at least 2 months after sulfas…
Contacts